FAQ on Tonix Pharmaceuticals' TNX-1700 as an Immunotherapy Enhancer in Gastric Cancer
Summary
Tonix Pharmaceuticals has published preclinical data showing its candidate TNX-1700 enhances immunotherapy in gastric cancer by reducing metastases and improving survival in mouse models, supporting its development for overcoming checkpoint resistance in solid tumors.
What is TNX-1700 and what does it do?
TNX-1700 is a fusion protein candidate developed by Tonix Pharmaceuticals in collaboration with Columbia University Medical School, designed to enhance anti-PD-1 immunotherapy by depleting immunosuppressive neutrophils and curbing cancer-driven granulopoiesis, showing promise in increasing survival and reducing metastases in gastric cancer mouse models.
Why is the development of TNX-1700 significant?
The development of TNX-1700 is significant because it offers a potential solution to overcome checkpoint resistance in solid tumors, such as gastric and colorectal cancers, by enhancing the effectiveness of immunotherapy.
How does TNX-1700 work?
TNX-1700 works by combining murine trefoil factor-2 (mTFF2) with murine serum albumin to enhance anti-PD-1 immunotherapy, effectively depleting immunosuppressive neutrophils and inhibiting cancer-driven granulopoiesis, which are key mechanisms in cancer progression.
Who is involved in the development of TNX-1700?
Tonix Pharmaceuticals, in collaboration with Columbia University Medical School, is developing TNX-1700, with CEO Dr. Seth Lederman highlighting the findings as supportive of further development for solid tumors.
Where can I find more information about TNX-1700 and Tonix Pharmaceuticals?
More information about TNX-1700 and Tonix Pharmaceuticals can be found on the company’s website at www.TonixPharma.com and in the full press release at https://ibn.fm/PPxKC.
What other products is Tonix Pharmaceuticals developing?
Tonix Pharmaceuticals is also developing TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, TNX-1500 for organ transplant rejection and autoimmune diseases, and TNX-4200 as a broad-spectrum antiviral, among others in CNS disorders, immunology, rare diseases, and infectious diseases.
Has TNX-1700 been tested in humans?
The content mentions preclinical findings in mouse models, indicating that TNX-1700 is in development for human use in gastric and colorectal cancers, but does not specify human trials at this stage.
What are the next steps for TNX-1700?
The next steps for TNX-1700 involve further development to overcome checkpoint resistance in solid tumors, based on the promising preclinical data showing its potential to enhance immunotherapy effectiveness.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99419